Walder Wyss Ltd.

Nous recherchons un·e avocat·e en droit des successions passionné·e et expérimenté·e pour rejoindre notre équipe ! Vous avez plusieurs années d’expérience en étude d’avocats ? Vous maîtrisez parfaitement le français et l’anglais, et avez une bonne connaissance passive de l'allemand ? Pour en savoir plus sur le poste vacant, cliquez ici: https://lnkd.in/eHmK4mNT

We had an incredible event where our experts shared invaluable insights on relocating to Switzerland! Our immigration specialist, Samantha Thomann Brand, tax expert, Marius Breier, and private client advisor, Kinga M. Weiss, provided a comprehensive overview of the most important Swiss rules, especially for non-EU nationals. They presented real-life case studies, shared dos and don'ts, and highlighted the latest developments in the field.   Whether you are considering a move or advising clients on relocation, this session was packed with practical tips and essential information to make the transition smooth and successful.   Our teams are happy to assist you with any questions you may have on this subject. Stay tuned for upcoming events and further insights on this topic!   #Relocation #Switzerland #Immigration #Tax #PrivateClient #ExpertAdvice #GlobalMobility #EventRecap

Nous recherchons un·e assistant·e juridique dynamique et rigoureux·se pour notre département Arbitrage de Genève ! 🔍 Vous avez une expérience dans une étude d'avocats ? Vous êtes autonome, flexible et avez le sens de la confidentialité ? Alors, nous avons une opportunité pour vous ! Pour en savoir plus sur le poste vacant, cliquez ici: https://lnkd.in/dcpEcRft #hiring #lawjob #walderwyssgeneva

Walder Wyss advised the founders Christopher Kindl and Severin Landolt on the sale of all shares in Tremor Labs, Inc. to Vercel Inc. Tremor Labs is a Y-Combinator startup providing an open-source product for building charts and dashboards.   The team was led by Alice Vorburger (Corporate/M&A, Managing Associate) and Ramona Wyss (Transaction/Regulatory, Partner) and further included Carmen Spichiger (Corporate/M&A, Senior Associate), Fabienne Limacher (Tax, Partner), Daniela Hottiger (Tax, Associate) and Angelina Lorena Pellegrini (Employment, Senior Associate). https://lnkd.in/dp8PEZ4H

Swiss IP News: In this newsletter, we provide you with updates on new decisions, the relevant legislative process and other trends in the fields of intellectual property and unfair competition law from a Swiss perspective. "Only One Version of the Patent Claim Allowed in Preliminary Injunction Proceedings" by Manuel Bigler and Markus Frick: https://lnkd.in/d4gZBUXN "Raising the Bar on Climate Claims: Switzerland’s New Greenwashing Rules" by Sylvia Anthamatten and Andreas Hösli: https://lnkd.in/dgU_83S3 Link to all articles: #intellectualproperty #swissipnews #walderwyss

The World Trademark Review has just released its WTR 1000 Ranking 2025, and we have achieved remarkable recognition!   The WTR 1000 is the definitive guide that identifies the top trademark professionals across key jurisdictions worldwide.   The Walder Wyss team achieves gold status in enforcement and litigation. In addition, our lawyers Alain Alberini, Sylvia Anthamatten, Stefano Codoni, Markus Frick, Michael Isler and Roger Staub were recognised as highly recommended individuals in this year's edition.   Thank you to our incredible team and valued clients for your continuous support. Together, we are setting new standards in trademark practice! https://lnkd.in/dX-BX-q8   #WTR1000 #TrademarkExperts #LegalExperts #walderwyss

Since 1 July 2023, cross-border commuters have been allowed to work from home for up to 49.9% of their working time under certain conditions. A legislative change that came into effect at the beginning of the year introduces further documentation requirements for employers who employ cross-border commuters residing in France if these individuals work (part of their working time) from home. Read the full newsletter on the topic by our authors, Simone Wetzstein, Fabienne Limacher and Tabea Gutmann, here: https://lnkd.in/dciNU4Qn #EmploymentNews #EmploymentLaw #SwissImmigration #LegalInsights #WalderWyss

Novo Holdings A/S, a leading global life science investor, has completed in December 2024 its previously announced acquisition of Catalent, Inc., a leader in enabling the development and supply of better treatments for patients worldwide, in an all-cash transaction with a total enterprise value of approximately $16.5 billion. In connection with the transaction, Novo Holdings will sell three of Catalent’s nearly 50 global sites to Novo Nordisk A/S. Catalent is a leading partner to some of the most innovative biopharma companies in the world. Over the past 10 years, Catalent has assisted in 50% of all FDA approvals, demonstrating the strength of its industry-leading clinical supply management capabilities. Walder Wyss advised Novo Holdings A/S on the Swiss aspects of the transaction. The team was co-led by Luc Defferrard (Partner, Corporate/M&A) and Iliana Djagova (Counsel, Corporate/M&A) and further included Simone Wetzstein (Partner, Employment Law), Fabienne Limacher (Partner, Tax), Sylvia Anthamatten (Counsel, IP/IT), Julia Lehner (Counsel, Real Estate), Fabian Looser (Counsel, Employment), Erik Lanz (Senior Associate, Corporate/M&A), Simon Olstein (Senior Associate, Life Sciences) and Christoph Burckhardt (Associate, Corporate/M&A). https://lnkd.in/dedpyE_S

RhyGaze, a biotechnology company based in Basel and Philadelphia announced that it has secured a Series A financing of USD 86 million. The round was led by GV (Google Ventures), alongside Arch Venture Partners, F-Prime Capital and founding investors BioGeneration Ventures and Novartis Venture Fund, who contributed USD 11 million to an earlier seed round.   RhyGaze was founded on intellectual property exclusively licensed to the company by the Institute of Molecular and Clinical Ophthalmology Basel (IOB), a scientific institute led by Director Botond Roska, M.D., Ph.D., who is a scientific co-founder of RhyGaze. This funding will enable further development of RhyGaze’s lead clinical candidate, a novel gene therapy for optogenetic vision restoration in diseases causing blindness. Activities to be supported include formal pharmacology and toxicology testing, a non-interventional, observational study to assess potential clinical endpoints in patient groups eligible for the therapy and a first-in-human clinical trial to test the safety, tolerability and potential efficacy of the lead candidate.   Walder Wyss advised RhyGaze since its foundation and in both financing rounds. The team was led by Robert von Rosen (Partner, Corporate/M&A) and further included Alexander Gutmans (Partner, Corporate/M&A and Venture Capital), Lucas Maurer (Associate, Corporate/M&A) and Dario Glauser (Associate, Employment).

On 27/28 January 2025, the Swiss Federal Tax Administration (SFTA) published the safe haven interest rates for 2025 to be used on intra-group loans. Against this backdrop, this article provides an overview of the relevant Swiss tax rules associated with determining whether intra-group financing constitutes equity or debt for tax purposes and the consequences of each characterisation. Read the full newsletter by our authors Fabienne Limacher and Maurus Winzap here: https://lnkd.in/eJg-jjus